KRAS and non-small cell lung carcinoma: Selective covalent inhibitors targeting KRASG12C, such as AMG-510 (sotorasib), have also emerged to combat constitutively active KRAS, but are currently only approved as a second line treatment in patients with non-small cell lung carcinoma [231, 232].